(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Terapia celular > DA - CIMA - Oncología - Terapia celular - Artículos de Revista >

Multipotent adult progenitor cell transplantation increases vascularity and improves left ventricular function after myocardial infarction
Autor(es) : Pelacho, B. (Beatriz)
Nakamura, Y. (Yasuhiro)
Zhang, J. (Jianyi)
Ross, J. (Jeff)
Heremans, Y. (Y.)
Nelson-Holte, M. (Molly)
Lemke, B. (Brad)
Hagenbrock, J. (J.)
Jiang, Y. (Y.)
Prosper, F. (Felipe)
Luttun, A. (Aernout)
Verfaillie, C.M. (Catherine M.)
Palabras clave : Adult stem cells
Bone marrow
Acute myocardial infarction
Angiogenesis
Cellular therapy
Fecha incorporación: 2007
Editorial : Wiley-Blackwell
Versión del editor: http://dx.doi.org/10.1002/term.7
ISSN: 1932-6254
Cita: Pelacho, B., Nakamura, Y., Zhang, J., Ross, J. et al. Multipotent adult progenitor cell transplantation increases vascularity and improves left ventricular function after myocardial infarction. J Tissue Eng Regen Med 2007; 1: 51–59
Resumen
Progressive contractile dysfunction of viable myocardium that surrounds a large infarct leads to heart failure following acute myocardial infarction (AMI). Experimental evidence indicates that cellular transplantation may improve the left ventricular (LV) contractile performance, even though the underlying mechanisms remain undefined. Here, we compared the effect of transplantation of murine multipotent adult progenitor cells (MAPCs), a population of adult bone marrow-derived cells that differentiate into cells of mesodermal, endodermal and ectodermal origin, with murine bone marrow cells (BMCs) or fibroblasts on post-infarct cardiac function by peri-infarct injection after coronary artery ligation in mice. We demonstrate that, in contrast to the other cell populations, transplantation of MAPCs significantly improved LV contractile function for at least 8 weeks posttransplantation and, although BMCs reduced infarct size, the decrease in scar size was substantially greater in MAPC-treated hearts. As neither MAPCs nor BMCs were present beyond 1 week, the beneficial effect was not due to differentiation and direct contribution of MAPCs to the vascular or cardiomyocyte compartment. Significantly more inflammatory cells were present in MAPC- than BMC-treated hearts at 1 week, which was accompanied by increased vascularity 8 weeks posttransplantation. We hypothesize that MAPCs indirectly contributed to these effects, by secreting inflammatory [monocyte chemoattractant protein-1 (MCP)-1], and vascular growth factors [vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-BB, and transforming growth factor (TGF)β1), and others, resulting in increased angiogenensis and cardioprotection.
Enlace permanente: http://hdl.handle.net/10171/18352
Aparece en las colecciones: DA - CIMA - Oncología - Síndromes mieloproliferativos - Artículos de Revista
DA - CIMA - Oncología - Terapia celular - Artículos de Revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Ficheros en este registro:

No hay ficheros asociados a este ítem.

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.